Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Medina Sanchez

Physical Medicine & Rehabilitation Tampa, FL Medical Doctor

NPI 1619121324 CMS profile 254959

3450 E Fletcher Ave, Ste 350, Tampa, FL 33613

Open in the dashboard

General payments

$30,192

587 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Medina Sanchez of Tampa, FL is reported in the CMS Open Payments database as having received $30,192 across 587 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,164 81
2024 General $1,668 86
2023 General $6,225 76
2022 General $5,071 98
2021 General $3,207 95
2020 General $8,986 53
2019 General $2,873 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Medina Sanchez
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jose Medina Sanchez were reported at $2,164. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jose Medina Sanchez Physical Medicine & Rehabilitation median Middle half National median
2019 $2,873 $133 $45–$390 $163
2020 $8,986 $88 $29–$272 $114
2021 $3,207 $116 $33–$360 $132
2022 $5,071 $123 $40–$378 $149
2023 $6,225 $131 $43–$396 $160
2024 $1,668 $141 $45–$409 $164
2025 $2,164 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nutech Spine, Inc. $11,255 13 payments
  2. Medtronic, Inc. $7,659 116 payments
  3. Abbott Laboratories $1,441 37 payments
  4. Genesys Orthopedics Systems, L.L.C. $1,232 6 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,001 51 payments
  6. Collegium Pharmaceutical, Inc. $791 51 payments
  7. Amgen Inc. $718 48 payments
  8. Nevro Corp. $654 26 payments
  9. Medtronic USA, Inc. $612 32 payments
  10. AbbVie, Inc. $611 30 payments
  11. Other $4,218 177 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,549 555 payments
  2. Consulting Fee $9,400 6 payments
  3. Travel and Lodging $4,306 20 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,470 1 payment
  5. Entertainment $344 1 payment
  6. Education $109 3 payments
  7. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $6,908 77 payments
  2. SiFix $2,971 5 payments
  3. Sacroiliac Joint Fusion System $1,232 6 payments
  4. AIMOVIG $795 51 payments
  5. XTAMPZA $744 49 payments
  6. RELISTOR $650 41 payments
  7. PROCLAIM $642 13 payments
  8. Intracept Pain $564 13 payments
  9. NURTEC ODT $486 18 payments
  10. Intracept Pain $486 6 payments
  11. Other $8,127 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

8,445

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$372,089

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

52.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,915 $70,328
Relistor Methylnaltrexone Bromide Brand 21 $50,115
Oxycodone Hcl Generic 2,282 $46,685
Xtampza Er Oxycodone Myristate Brand 89 $46,574
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,535 $43,370
Belbuca Buprenorphine Hcl Brand 45 $26,922
Oxycontin Oxycodone Hcl Brand 18 $14,648
Morphine Sulfate Er Morphine Sulfate Brand 637 $14,345
Pregabalin Generic 266 $8,307
Hydromorphone Er Hydromorphone Hcl Brand 12 $6,535

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$104,390

Of which drugs: $209

Medicare patients

215

Average age 65

Services billed

3,620

131 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 48%
Diabetes 39%
Ischemic heart disease 31%
COPD 31%
Chronic kidney disease 28%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 236 $179
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 18 2,330 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $296
$296 21 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $240
$240 89 —
QULIPTA
  • AbbVie, Inc. $72
$72 — —
NURTEC ODT
  • PFIZER INC. $50
$50 — —
EMGALITY
  • Lilly USA, LLC $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

587 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record